Covance Not Cooling...
Health Care: Drugs
Orexigen Therapeutics Inc. (OREX: NASDAQ)
$6.02 -0.02 | -0.33%
05/20/13 - 04:00 PM ET
Portfolios with OREX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- User2012 picks 10/28/20121
- ContributorBreakout Stocks Of The Week...
- Usermy picks
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor5 Stocks Under-$10 Setting ...
- UserBlind Rookie
Latest OREX Headlines from TheStreet
- 8 Stocks Under $10 Moving Higher 02.28.13 | 11:02 pm
- J.P. Morgan Healthcare Confab Live Blog Day Two 01.08.13 | 11:01 am
- J.P. Morgan: Biotech Stocks Heading Higher in 2013 01.02.13 | 07:01 am
- Biotech Stock Mailbag: More Amarin, MannKind, Orexigen 11.02.12 | 07:11 am
- Vivus Weight-Loss Drug's Failing Math 10.31.12 | 01:10 pm
- 5 Stocks Poised for Breakouts 10.26.12 | 01:10 pm
- Orexigen Therapeutics' CEO Presents At Bank Of America Merrill Lynch Global Healthcare Conference - Special Call Transcript 09.13.12 | 12:09 pm
- Orexigen Therapeutics' CEO Presents At Morgan Stanley Healthcare Conference (Transcript) 09.12.12 | 12:09 pm
- 4 Biotech Stocks Under $5 Moving Higher 09.05.12 | 03:09 pm
- Orexigen Therapeutics CEO Discusses Q2 2012 Results - Earnings Call Transcript 08.07.12 | 11:08 am
Press Releases for OREX
- Orexigen Therapeutics To Host Full Year And Fourth Quarter 2012 Financial Results Conference Call And Webcast - PR Newswire 03.07.13 | 08:03 am
- Orexigen Therapeutics Announces Progress With FDA On A Faster Path To Resubmission Of The Contrave NDA - PR Newswire 01.07.13 | 08:01 am
- Orexigen Therapeutics Concludes Light Study Patient Screening, Expecting To Randomize Approximately 9,000 Patients, And Presents New Obesity Therapeutics Market Research - PR Newswire 12.18.12 | 08:12 am
- Orexigen Therapeutics To Host Analyst Day Event On December 18, 2012 - PR Newswire 12.04.12 | 08:12 am
- Orexigen Therapeutics Schedules November 7, 2012 Conference Call And Webcast Discussion Of Financial Results For The Third Quarter Ended September 30, 2012 - PR Newswire 10.31.12 | 08:10 am
- Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion Of Financial Results For The Second Quarter Ended June 30, 2012 - PR Newswire 07.31.12 | 04:07 pm
- Orexigen® Therapeutics And Sharecare® Announce Partnership For WeightMateâ¢, A Comprehensive Weight Management Program - PR Newswire 06.06.12 | 06:06 am
- The Light Study, A Long-Term Research Study Of Investigational Weight Loss Drug Contrave®, Begins Enrolling Patients Nationwide - PR Newswire 06.06.12 | 06:06 am
- Orexigen® Therapeutics Completes Public Offering Of Common Stock And Warrants To Purchase Common Stock - PR Newswire 12.22.11 | 04:12 pm
- Orexigen Therapeutics To Present At The Lazard Capital Markets Healthcare Conference - PR Newswire 11.11.11 | 08:11 am
Partner Headlines for OREX
- Vivus And Anti-Obesity Sector Benefit From New Insurance Deal - Seeking Alpha 05.01.13 | 09:05 am
- Orexigen: The Best Bet In Obesity For 2013 - Seeking Alpha 12.17.12 | 09:12 am
- Vivus Reports A Weak 1st Quarter For Qsymia - Seeking Alpha 11.08.12 | 09:11 am
- The right data is key to spotting trends - NASDAQ 09.21.12 | 02:09 pm
- Vivus Launches Obesity Drug Qsymia - Analyst Blog - NASDAQ 09.20.12 | 10:09 pm
- Vivus Launches Obesity Drug Qsymia - Analyst Blog - Zacks 09.20.12 | 06:09 pm
- Buy Zalicus For A 120% Upside - Seeking Alpha 09.05.12 | 09:09 am
- Investing in Biotech Stocks? The Journey to Profits Requires a Good GPS - NASDAQ 08.31.12 | 04:08 pm
- Arena And Vivus Set To Dominate The Obesity Drug Market - Seeking Alpha 08.30.12 | 09:08 am
- Arena Cuts Loss, Sales Climb - Analyst Blog - Zacks 08.14.12 | 09:08 am
